Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 70/100

REGENXBIO to Participate in Upcoming Investor Conferences

Monday, May 18, 2026 2 min read
Key Takeaway: REGENXBIO Inc. has announced its participation in two upcoming investor conferences, highlighting its continued engagement with the investment community. The events include the RBC Capital Markets Global Healthcare Conference and the Stifel Virtual Ophthalmology Forum. REGENXBIO aims to showcase its advancements in gene therapy, particularly its late-stage treatments for rare and retinal diseases. The company has been a pioneer in AAV gene therapy since its inception in 2009.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO is actively engaging with investors through multiple conferences.
  • The company is recognized for its innovative work in gene therapy.
  • There is a growing interest in REGENXBIO's late-stage pipeline of one-time gene therapies.

Full Press Release Details

ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
2026 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 20 at 9:30am ET
Location: New York, NY
Stifel 2026 Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 26 at 9:30am ET
Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Corporate Communications
George E. MacDougall
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What conferences will REGENXBIO participate in?

REGENXBIO will participate in the RBC Capital Markets Global Healthcare Conference and the Stifel 2026 Virtual Ophthalmology Forum.

When is the RBC Capital Markets Conference fireside chat?

The fireside chat at the RBC Capital Markets Conference is on May 20, 2026, at 9:30am ET.

How can I access the webcasts of the events?

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website.

What is REGENXBIO's focus in biotechnology?

REGENXBIO focuses on improving lives through the curative potential of gene therapy.

What diseases are addressed by REGENXBIO's pipeline?

REGENXBIO's pipeline targets rare and retinal diseases, including Duchenne and MPS disorders.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy investor conferences ophthalmology
Last updated: May 18, 2026